{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:35:37Z","timestamp":1789598137428,"version":"build-2803163510"},"reference-count":53,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Uncomplicated bacteremic urinary tract infections (bUTIs) are common, often caused by\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      ,\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      , and\n                      <jats:italic>Enterococcus faecalis<\/jats:italic>\n                      , with most encounters treated empirically. As rates of antimicrobial resistance increase, available antibiotic treatment options are dwindling. Novel antibiotics approved for treating bUTIs are limited, leading to a resurgence of interest in older antibiotics, including fosfomycin. Here, clinical urine samples from patients including military personnel, retirees, and their dependents diagnosed with bUTIs from a military hospital located in Bethesda, Maryland, were tested for susceptibility to fosfomycin and comparator antibiotics (levofloxacin, nitrofurantoin, and trimethoprim-sulfamethoxazole [TMS]). A total of 1,353 nonduplicate bacterial isolates were tested, including 605 non-ESBL and 285 ESBL\n                      <jats:italic>E. coli<\/jats:italic>\n                      , and 84 non-ESBL and 52 ESBL\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      . Fosfomycin susceptibility rates were similar for non-ESBL and ESBL\n                      <jats:italic>E. coli<\/jats:italic>\n                      (95.9% vs 96.1%) and\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      (38.1% vs 36.5%). Fosfomycin demonstrated high activity against other Enterobacterales and gram-positive organisms including\n                      <jats:italic>Enterobacter faecalis<\/jats:italic>\n                      and\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      . Interestingly, most fosfomycin non-susceptible isolates were susceptible to other first-line bUTI treatment options, and most isolates that were non-susceptible to other first-line bUTI treatment option were susceptible to fosfomycin. ESBL\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      isolates were the least susceptible to current first-line treatment options. Fosfomycin Etest demonstrated high sensitivity compared to agar dilution, making it a viable AST testing method especially in resource-limited areas. Overall, we demonstrated fosfomycin has high activity against common etiologies that cause bUTIs. Further clinical efficacy studies investigating the use of fosfomycin in treating non-\n                      <jats:italic>E<\/jats:italic>\n                      .\n                      <jats:italic>coli<\/jats:italic>\n                      bUTI pathogens, as single or combination therapy, are warranted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>IMPORTANCE<\/jats:title>\n                    <jats:p>\n                      Uncomplicated bUTIs are often caused by\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      ,\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      , and\n                      <jats:italic>Enterococcus faecalis<\/jats:italic>\n                      . Fosfomycin is one of the recommended firstline antibiotics for the treatment of symptomatic, uncomplicated bUTIs. Fosfomycin susceptibility testing is complicated by the fact that although both CLSI and EUCAST recognize agar dilution (AD) as the reference method albeit being labor-intensive, breakpoints are different, and Etest is only approved by EUCAST. We investigated the susceptibility of bUTI clinical isolates to fosfomycin using AD and compared performance in a subset of isolates to Etest. Fosfomycin susceptibility profiles of bacterial isolates were compared to other firstline antibiotics. We found isolates were susceptible to fosfomycin at similar or higher rates compared to other firstline antibiotics. Importantly, fosfomycin was effective against isolates producing extended-spectrum beta-lactamases and those that were resistant to other firstline treatments. Furthermore, our data showed Etest was a viable option for susceptibility testing with 94% agreement to the AD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.01860-24","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T09:03:42Z","timestamp":1738746222000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Antimicrobial susceptibilities of clinical bacterial isolates from urinary tract infections to fosfomycin and comparator antibiotics determined by agar dilution method and automated micro broth dilution"],"prefix":"10.1128","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3017-5221","authenticated-orcid":false,"given":"Jamie L.","family":"Dombach","sequence":"first","affiliation":[{"name":"Department of Clinical Investigations, Tripler Army Medical Center","place":["Honolulu, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy C.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pathology and Area Laboratory Services, Walter Reed National Military Medical Center","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Kottiri","sequence":"additional","affiliation":[{"name":"Department of Pathology and Area Laboratory Services, Walter Reed National Military Medical Center","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Schiller","sequence":"additional","affiliation":[{"name":"Department of Clinical Investigations, Tripler Army Medical Center","place":["Honolulu, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-7883","authenticated-orcid":true,"given":"Edwin","family":"Kamau","sequence":"additional","affiliation":[{"name":"Department of Pathology and Area Laboratory Services, Walter Reed National Military Medical Center","place":["Bethesda, USA"]},{"name":"Department of Pathology and Area Laboratory Services, Tripler Army Medical Center","place":["Honolulu, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.UTI-0002-2012"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1121"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0150-5"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.4102\/sajid.v37i1.321"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.020"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.02.001"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.166.3901.122"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00068-15"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.039"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.17.1897"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2010.22.5.355"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37277"},{"key":"e_1_3_4_15_2","volume-title":"M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. Performance standards for anmicrobial susceptibility testing; twenty-third informational supplement. In M100-S23. Clinical and Laboratory 423 Standards Institue, Wayne, PA."},{"key":"e_1_3_4_16_2","volume-title":"M7-A8, 8th ed","author":"Clinical and Laboratory Standards Institute 2009","year":"2009","unstructured":"Clinical and Laboratory Standards Institute 2009. 2009. Methods for dilution susceptibility tests for bacteria that grow aerobically; approved standard. In M7-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01121-20"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad147"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad016"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02136-23"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.26574\/maedica.2023.18.4.593"},{"key":"e_1_3_4_22_2","unstructured":"Ten Doesschate T Kuiper S Nieuwkoop C. 2021. FORECAST study team. fosfomycin versus ciprofloxacin as oral stepdown treatment for Escherichia coli febrile urinary tract infection in women: a randomized placebo-controlled double blind multicenter trial Clin Infect Dis:ciab934."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-007-0456-4"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq237"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.10.019"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70325-1"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02921.x"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2011.616221"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00349-11"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2013.04.005"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-017-0222-6"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02614-15"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0924-8579(98)00021-1"},{"key":"e_1_3_4_34_2","first-page":"17","article-title":"A Comparison of Cephalexin with Fosfomycin Trometanol (monurol) in the treatment of pregnant women with lower urinary tract","volume":"13","author":"Karimi A","year":"2012","unstructured":"Karimi A, Afrakhteh M, Aghazadeh Naeini A, Amiri Z. 2012. A Comparison of Cephalexin with Fosfomycin Trometanol (monurol) in the treatment of pregnant women with lower urinary tract. Yafteh 13:17\u201322.","journal-title":"Yafteh"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12040623"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics6040024"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0794-5"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1360-5"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000100811"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s101560200004"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709477"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02522"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.12.005"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006723"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24843"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3627"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad557"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1159\/000512582"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38919-8"},{"key":"e_1_3_4_50_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2022. Breakpoint tables for interpretation of MICs and zone diameters; version 12.0. Available from: http:\/\/www.eucast.org"},{"key":"e_1_3_4_51_2","volume-title":"M100-S32","year":"2022","unstructured":"Performance standards for anmicrobial susceptibility testing; thirty-second informa onal supplement. 2022. In M100-S32. Clinical and 574 Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00021-22"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03363-22"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.06.014"}],"container-title":["Microbiology Spectrum"],"original-title":[],"contributor":[{"given":"Janet A.","family":"Hindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"reviewer"}]}],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01860-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01860-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:10:26Z","timestamp":1741079426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01860-24"}},"subtitle":[],"editor":[{"given":"Bonnie Chase","family":"Prokesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,4]]}},"alternative-id":["10.1128\/spectrum.01860-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01860-24","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.25.24311029","asserted-by":"object"}]},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"2024-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01860-24"}}